Medical News

RSS

Mount Sinai researchers to study why African Americans less likely to receive CRC screenings

Researchers at the Icahn School of Medicine at Mount Sinai have received a multi-year National Institutes of Health grant to determine factors which may influence why African Americans are less likely than others to receive colorectal cancer screenings, despite having the highest CRC incidence and mortality of any ethnic/racial group in America.

5 Sep 2013

Research: Men who exercise vigorously may reduce risk of epilepsy later in life

New research suggests that men who exercise vigorously as young adults may reduce their risk of developing epilepsy later in life. The study is published in the September 4, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology. Epilepsy is a brain disease that causes repeated seizures over time.

5 Sep 2013

New technique use finger's pulse to measure stiffness in aorta

A University of Iowa physiologist has a new technique to measure the stiffness of the aorta, a common risk factor for heart disease. And it can be as simple as measuring the pulse in your finger.

5 Sep 2013

Researchers find no difference in stage-adjusted lung cancer mortality between blacks and whites

According to the American Cancer Society, an estimated 160,340 lung cancer deaths occurred in the United States in 2012, accounting for 28 percent of all cancer deaths. While survival from lung cancer has improved since the early 1990s, racial differences in lung cancer survival persist such that blacks experience poorer 5-year survival for lung cancer compared to whites.

5 Sep 2013

High-income and better hygiene countries exhibit much higher rates of Alzheimer's

New research has found a "very significant" relationship between a nation's wealth and hygiene and the Alzheimer's "burden" on its population. High-income, highly industrialised countries with large urban areas and better hygiene exhibit much higher rates of Alzheimer's.

5 Sep 2013

Parkin protein plays key role in destruction of bacteria that cause tuberculosis

A protein at the center of Parkinson's disease research now also has been found to play a key role in causing the destruction of bacteria that cause tuberculosis, according to scientists led by UC San Francisco microbiologist and tuberculosis expert Jeffery Cox, PhD.

5 Sep 2013

Underweight women with CAD should gain weight to reduce risk of death

Being underweight increases the death risk of women with coronary artery disease (CAD) by 2-fold, according to research presented at the ESC Congress today by Dr Aziza Azimi from Denmark. The study suggests that underweight women with CAD should gain weight to reduce their risk of death.

5 Sep 2013

Research findings raise hope for new heart therapies

Many people who survive a heart attack find themselves back in the hospital with a failing heart just years later. And the outcome often is unfavorable, owing to limited treatment options. But scientists at Temple University School of Medicine's Cardiovascular Research Center recently found hope in an unlikely source - stem cells in cortical, or compact, bone.

5 Sep 2013

Resveratrol improves cognition and reduces oxidative stress in rats with vascular dementia

Resveratrol, a polyphenolic compound, is synthesized in several plants and possesses beneficial biological effects, which include anti-oxidant, anti-inflammatory and anti-carcinogenic properties.

5 Sep 2013

Latest study recommends accelerated radiotherapy for un-resected NSCLC patients

Radiotherapy with or without chemotherapy is increasingly being used in the curative treatment for un-resected non-small cell lung cancer (NSCLC). But, until now, researchers had not looked at the cost-effectiveness of the treatment.

5 Sep 2013

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.

5 Sep 2013

Southampton researchers investigates influence of mechanical forces on cellular, molecular processes

University of Southampton researchers are at the forefront of research into mechanobiology, an emerging field of science combining biology and engineering, which investigates the influence of mechanical forces on cellular and molecular processes.

5 Sep 2013

People with CVD more likely to take preventive medicines when combined in one pill

People are much more likely to take preventive medicines if they're combined in one pill, an international study has found. The findings are published today in the Journal of the American Medical Association.

5 Sep 2013

Michigan gives final green light to Medicaid expansion

The Republican-led Michigan House gave final approval on Tuesday to a bill that would expand the Medicaid health program for the poor under Democratic President Barack Obama's healthcare reform law. Representatives voted 75-32 to concur with modifications of a bill that they had approved in June and agreed to send it to Michigan Governor Rick Snyder, a Republican who has backed the expansion of the Medicaid program (Bailey, 9/3).

5 Sep 2013

Neurodyn acquires all assets related to new drug candidate Memogain from Galantos Pharma

Neurodyn Inc. announced today that it has acquired from Galantos Pharma GmbH, Mainz, Germany all assets related to their Alzheimer's prescription drug candidate - Memogain. Memogain has completed an extensive preclinical development program and is ready to proceed into Phase 1 clinical trials in late 2013. The terms of the acquisition were not disclosed.

5 Sep 2013

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Affinium Pharmaceuticals announced today that it has initiated dosing in a Phase 1 intravenous clinical trial of its new antibiotic prodrug, AFN-1720. AFN-1720 is the prodrug of the active drug, AFN-1252.

5 Sep 2013

Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Sanofi US and POZEN Inc. announced the signing of an exclusive license agreement for the commercialization of POZEN's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor, and enteric-coated aspirin in a single tablet ("PA"), PA8140 and PA32540.

5 Sep 2013

Medical News

Mount Sinai researchers to study why African Americans less likely to receive CRC screenings

Research: Men who exercise vigorously may reduce risk of epilepsy later in life

New technique use finger's pulse to measure stiffness in aorta

Researchers find no difference in stage-adjusted lung cancer mortality between blacks and whites

High-income and better hygiene countries exhibit much higher rates of Alzheimer's

Parkin protein plays key role in destruction of bacteria that cause tuberculosis

Underweight women with CAD should gain weight to reduce risk of death

Research findings raise hope for new heart therapies

Resveratrol improves cognition and reduces oxidative stress in rats with vascular dementia

Latest study recommends accelerated radiotherapy for un-resected NSCLC patients

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Southampton researchers investigates influence of mechanical forces on cellular, molecular processes

People with CVD more likely to take preventive medicines when combined in one pill

Michigan gives final green light to Medicaid expansion

Neurodyn acquires all assets related to new drug candidate Memogain from Galantos Pharma

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Dementia risk for bipolar disorder patients

Menopause findings show asthma to be ‘women’s health issue’

Increased mortality in schizophrenia ‘not attributable to drug therapy’

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Latest News